PTK2 and neoplasm: TAE226 (2-(5-chloro-2-(2-methoxy-4-(4-morpholinyl)phenylamino)pyrimidin-4-ylamino)-N-methylbenzamide), a potent adenosine triphosphate (ATP)-competitive FAK inhibitor, has also demonstrated significant antiproliferative and antitumor effects in glioblastoma cells, markedly reducing cell survival in a concentration- and time-dependent manner (64) (64).However, TAE226 exhibited minimal to no effect on enhancing radiosensitivity, suggesting that its efficacy may be tumor type-dependent and highlighting the importance of selecting inhibitors based on tumor-specific biology (64).